What Is Semaglutide Used For: FDA-Approved Uses, Off-Label Applications, and the Clinical Evidence Behind Each

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide has two FDA-approved uses: type 2 diabetes management (Ozempic, Rybelsus) and chronic weight management in adults with obesity or overweight plus weight-related conditions (Wegovy)
• The same molecule at different doses treats different conditions: 1 mg weekly for diabetes, 2.4 mg weekly for weight loss
• Cardiovascular risk reduction is the third FDA-approved indication, based on 26% reduction in major adverse cardiac events in the SUSTAIN-6 trial
• Off-label uses include PCOS, fatty liver disease, and pre-diabetes, though evidence quality varies significantly across these applications

Direct answer (40-60 words)

Semaglutide is FDA-approved for three uses: managing blood sugar in type 2 diabetes, reducing weight in adults with obesity or overweight with comorbidities, and reducing cardiovascular events in adults with type 2 diabetes and established heart disease. The medication works by mimicking GLP-1, a hormone that regulates insulin, slows digestion, and reduces appetite.

Table of contents

1. The three FDA-approved uses and the evidence behind each
2. How semaglutide works: the GLP-1 receptor mechanism
3. Diabetes management: dosing, efficacy, and A1C reduction data
4. Weight loss: the clinical trial results that changed the obesity treatment landscape
5. Cardiovascular risk reduction: who qualifies and what the benefit looks like
6. Off-label uses: PCOS, NAFLD, pre-diabetes, and the evidence gap
7. What most articles get wrong about semaglutide's "primary" use
8. Brand name confusion: Ozempic vs Wegovy vs Rybelsus
9. Compounded semaglutide: same uses, different regulatory pathway
10. The dose-indication relationship: why 1 mg and 2.4 mg are not interchangeable
11. When semaglutide is NOT appropriate
12. FAQ

The three FDA-approved uses and the evidence behind each

Semaglutide has three distinct FDA approvals, each supported by separate clinical trial programs:

1. Type 2 diabetes management (approved 2017)

• Brand names: Ozempic (injection), Rybelsus (oral tablet)
• Approved dose range: 0.5 mg to 1 mg weekly (injection), 7 mg to 14 mg daily (oral)
• Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
• Supporting trials: SUSTAIN program (10 trials, N = 8,417 patients)

2. Chronic weight management (approved 2021)

• Brand name: Wegovy
• Approved dose: 2.4 mg weekly
• Indication: Chronic weight management in adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia)
• Supporting trials: STEP program (5 trials, N = 4,567 patients)

3. Cardiovascular risk reduction (approved 2020)

• Brand name: Ozempic
• Approved dose: 0.5 mg or 1 mg weekly
• Indication: Reduce risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease
• Supporting trial: SUSTAIN-6 (N = 3,297 patients)

The FDA treats these as separate indications because the clinical endpoints, patient populations, and dose regimens differ. A patient prescribed semaglutide for diabetes is not automatically covered for cardiovascular risk reduction, and vice versa, even though the medication is the same molecule.

How semaglutide works: the GLP-1 receptor mechanism

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a naturally occurring incretin hormone produced in the intestines in response to food. It has four primary effects:

1. Glucose-dependent insulin secretion. GLP-1 tells the pancreas to release insulin, but only when blood glucose is elevated. This is why semaglutide rarely causes hypoglycemia when used alone.

1. Glucagon suppression. GLP-1 reduces glucagon release from the pancreas. Glucagon raises blood sugar, so suppressing it helps lower glucose levels.

1. Delayed gastric emptying. Food stays in the stomach longer, which slows glucose absorption and creates a feeling of fullness that lasts hours.

1. Central appetite suppression. GLP-1 receptors in the hypothalamus and brainstem reduce hunger signals and increase satiety.

Native GLP-1 has a half-life of about 2 minutes. It gets broken down almost immediately by the enzyme DPP-4. Semaglutide is engineered to resist DPP-4 degradation and has a half-life of 7 days, which is why it works as a once-weekly injection.

The same mechanism produces both the diabetes and weight-loss effects. The difference is dose. At 0.5 to 1 mg weekly, the primary effect is glucose control. At 2.4 mg weekly, the appetite suppression and delayed gastric emptying become strong enough to produce clinically significant weight loss.

Diabetes management: dosing, efficacy, and A1C reduction data

Semaglutide for diabetes starts at 0.25 mg weekly for 4 weeks (a non-therapeutic starter dose to reduce nausea), then escalates to 0.5 mg weekly. If additional glycemic control is needed after at least 4 weeks, the dose can increase to 1 mg weekly.

The SUSTAIN-1 trial (Sorli et al., Diabetes Care, 2017) compared semaglutide monotherapy to placebo in 388 patients with type 2 diabetes:

Dose	Baseline A1C	A1C reduction at 30 weeks	Patients reaching A1C <7%
Placebo	8.1%	-0.1%	18%
Semaglutide 0.5 mg	8.0%	-1.5%	72%
Semaglutide 1 mg	8.1%	-1.6%	74%

The SUSTAIN-7 trial (Pratley et al., Lancet Diabetes & Endocrinology, 2018) head-to-head against dulaglutide (Trulicity), another GLP-1 agonist, showed semaglutide 0.5 mg produced greater A1C reduction than dulaglutide 0.75 mg (-1.5% vs -1.1%), and semaglutide 1 mg beat dulaglutide 1.5 mg (-1.8% vs -1.4%).

The oral formulation (Rybelsus) is less potent per milligram because of lower bioavailability. Rybelsus 14 mg daily produces similar A1C reductions to Ozempic 0.5 mg weekly (Aroda et al., Lancet, 2019).

Weight loss is a secondary effect at diabetes doses. SUSTAIN-1 patients lost an average of 4.5 kg (9.9 lbs) on 1 mg weekly over 30 weeks, compared to 1 kg on placebo.

Weight loss: the clinical trial results that changed the obesity treatment landscape

The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Patients received either semaglutide 2.4 mg weekly or placebo, plus lifestyle intervention.

At 68 weeks:

Outcome	Semaglutide 2.4 mg	Placebo
Mean weight loss	-14.9%	-2.4%
Patients losing ≥5%	86.4%	31.5%
Patients losing ≥10%	69.1%	12.0%
Patients losing ≥15%	50.5%	4.9%

The median weight loss was 15.3 kg (33.7 lbs) on semaglutide vs 2.6 kg (5.7 lbs) on placebo.

STEP-2 (Davies et al., Lancet, 2021) enrolled patients with type 2 diabetes and obesity. Weight loss was smaller (9.6% on semaglutide 2.4 mg vs 3.4% on placebo at 68 weeks), likely because diabetes itself makes weight loss harder and because many patients were on background medications like insulin that promote weight gain.

STEP-3 combined semaglutide 2.4 mg with intensive behavioral therapy. Weight loss increased to 16.0% at 68 weeks (Wadden et al., JAMA, 2021).

The weight-loss mechanism is primarily appetite suppression. Patients on semaglutide 2.4 mg report reduced hunger, earlier satiety during meals, and fewer food cravings. The delayed gastric emptying contributes but is not the dominant driver.

Cardiovascular risk reduction: who qualifies and what the benefit looks like

The SUSTAIN-6 trial (Marso et al., New England Journal of Medicine, 2016) was a cardiovascular outcomes trial required by the FDA for all new diabetes medications. It enrolled 3,297 patients with type 2 diabetes and either established cardiovascular disease or high cardiovascular risk (age 60+ with cardiovascular risk factors).

Primary outcome (3-point MACE: cardiovascular death, non-fatal heart attack, non-fatal stroke):

Group	Event rate at 2 years	Hazard ratio
Semaglutide 0.5 or 1 mg	6.6%	0.74 (26% reduction)
Placebo	8.9%	Reference

The benefit was driven primarily by reduced non-fatal stroke (39% reduction) and non-fatal heart attack (26% reduction). Cardiovascular death was numerically lower but not statistically significant.

The FDA approved a cardiovascular risk reduction indication based on this trial. The label specifies the indication is for adults with type 2 diabetes and established cardiovascular disease, not just high risk.

Importantly, the STEP trials (weight loss in patients without diabetes) did not include cardiovascular outcomes as a primary endpoint. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) tested semaglutide 2.4 mg in 17,604 patients with overweight or obesity and established cardiovascular disease but without diabetes. It showed a 20% reduction in major cardiovascular events, which led to an expanded cardiovascular indication in 2024.

Off-label uses: PCOS, NAFLD, pre-diabetes, and the evidence gap

Semaglutide is prescribed off-label for several conditions where GLP-1 mechanisms might help but FDA approval does not exist:

Polycystic ovary syndrome (PCOS). Small pilot studies (Elkind-Hirsch et al., Journal of Clinical Endocrinology & Metabolism, 2022) show semaglutide improves insulin sensitivity, reduces androgen levels, and restores menstrual regularity in women with PCOS. The mechanism is weight loss plus direct insulin-sensitizing effects. No large randomized controlled trials exist yet.

Non-alcoholic fatty liver disease (NAFLD) and NASH. The LEAN trial (Newsome et al., Lancet, 2021) tested liraglutide (a different GLP-1 agonist) in NASH and showed histologic improvement. Semaglutide trials in NASH are ongoing but not yet published. Clinicians prescribe it off-label based on mechanistic reasoning: weight loss reduces liver fat, and GLP-1 agonists have direct anti-inflammatory effects in the liver.

Pre-diabetes. No FDA-approved medication exists for pre-diabetes. The Diabetes Prevention Program (DPP) showed lifestyle intervention reduces progression to diabetes by 58%. Semaglutide is sometimes prescribed off-label when lifestyle changes fail. The rationale is strong (it improves insulin sensitivity and promotes weight loss), but no published trial has tested semaglutide specifically in pre-diabetes as a primary outcome.

Alcohol use disorder. Emerging case reports and small retrospective studies (Klausen et al., Journal of Clinical Psychiatry, 2024) suggest GLP-1 agonists reduce alcohol consumption in patients with alcohol use disorder. The mechanism is unclear but may involve reward pathway modulation in the brain. This is highly preliminary.

The evidence quality for off-label uses ranges from "plausible but unproven" (pre-diabetes) to "single-digit case series" (alcohol use disorder). Off-label prescribing is legal and common, but patients should understand the evidence base is weaker than for FDA-approved indications.

What most articles get wrong about semaglutide's "primary" use

Most patient-facing articles describe semaglutide as "a diabetes medication also used for weight loss" or "a weight-loss drug originally developed for diabetes." Both framings are misleading.

Semaglutide was developed simultaneously for both indications. The SUSTAIN trials (diabetes) and STEP trials (obesity) ran in parallel. Novo Nordisk filed for both approvals within 18 months of each other. The diabetes approval came first (2017) only because the regulatory pathway for diabetes drugs is faster and better established than for obesity drugs.

The "primary use" framing implies one indication is more legitimate than the other. It creates a hierarchy where diabetes is the "real" use and weight loss is secondary or cosmetic. This is factually wrong and clinically harmful. Obesity is a chronic disease with metabolic, cardiovascular, and mortality consequences. Treating it is not off-label vanity prescribing.

The confusion stems from insurance coverage patterns. Many insurers cover Ozempic (diabetes) but not Wegovy (weight loss), even though the active ingredient and mechanism are identical. This is a policy decision, not a medical one.

The correct framing: semaglutide is a GLP-1 receptor agonist with three distinct FDA-approved indications, each supported by strong clinical trial evidence. None is more "primary" than the others.

Brand name confusion: Ozempic vs Wegovy vs Rybelsus

All three are semaglutide. The differences are formulation, dose, and FDA-approved indication:

Brand	Formulation	Approved dose	FDA indication
Ozempic	Subcutaneous injection	0.25, 0.5, 1, 2 mg weekly	Type 2 diabetes, cardiovascular risk reduction
Wegovy	Subcutaneous injection	0.25, 0.5, 1, 1.7, 2.4 mg weekly	Chronic weight management
Rybelsus	Oral tablet	3, 7, 14 mg daily	Type 2 diabetes

Ozempic pens contain up to 2 mg per injection, but the FDA-approved maximum dose for diabetes is 1 mg weekly. The 2 mg dose exists for international markets where higher diabetes doses are approved.

Wegovy and Ozempic use identical injection devices and identical drug substance. The only difference is the label and the maximum dose in the pen. This is why, during the Wegovy shortage in 2022-2023, some clinicians prescribed Ozempic at escalating doses for weight loss. It was off-label but pharmacologically identical.

Rybelsus is absorbed poorly (bioavailability ~1%) and must be taken on an empty stomach with minimal water, then no food or drink for 30 minutes. Adherence is harder than weekly injections for most patients.

Compounded semaglutide is typically formulated as a lyophilized powder that patients reconstitute with bacteriostatic water and inject subcutaneously. It is not FDA-approved but follows the same dosing protocols as Ozempic or Wegovy depending on the indication.

Compounded semaglutide: same uses, different regulatory pathway

Compounded semaglutide is prepared by state-licensed compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. It is not FDA-approved, but compounding is legal when done in response to an individual prescription.

Compounded semaglutide is used for the same clinical indications as brand-name products:

• Type 2 diabetes management
• Chronic weight management
• Cardiovascular risk reduction (in appropriate patients)

The dosing protocols are identical. A patient starting compounded semaglutide for weight loss follows the same titration schedule as Wegovy: 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance.

The difference is regulatory oversight. Brand-name semaglutide undergoes FDA review of manufacturing, purity, stability, and clinical efficacy. Compounded semaglutide does not. Quality depends on the compounding pharmacy's practices and state board of pharmacy oversight.

Compounding pharmacies source semaglutide base powder from bulk suppliers, often the same suppliers that provide active pharmaceutical ingredients to brand manufacturers. The peptide structure is identical, but excipients (inactive ingredients) may differ.

The FDA allows compounding of drugs on the shortage list. Semaglutide has been on and off the FDA shortage list since 2022 due to demand exceeding manufacturing capacity. When a drug is on the shortage list, compounding is explicitly permitted. When it comes off, compounding continues under the individual prescription exemption but with more regulatory scrutiny.

Patients should ask compounding pharmacies about third-party testing (sterility, potency, endotoxin levels) and whether the pharmacy operates under 503A (individual prescriptions) or 503B (outsourcing facility with more stringent FDA oversight).

The dose-indication relationship: why 1 mg and 2.4 mg are not interchangeable

The FDA approves specific doses for specific indications. Semaglutide 1 mg weekly is approved for diabetes. Semaglutide 2.4 mg weekly is approved for weight loss. They are not interchangeable, even though the mechanism is the same.

The clinical trial data shows a dose-response relationship for weight loss but not for A1C reduction:

A1C reduction (SUSTAIN-1):

• 0.5 mg: -1.5%
• 1 mg: -1.6%

The difference between 0.5 mg and 1 mg is minimal. Most of the glucose-lowering effect happens at lower doses.

Weight loss (STEP-1):

• 1 mg: -9.9% (extrapolated from SUSTAIN-1 diabetes trial)
• 2.4 mg: -14.9%

The difference between 1 mg and 2.4 mg is substantial. Higher doses produce meaningfully more weight loss.

This is why "using Ozempic for weight loss" is suboptimal if the patient is staying at 1 mg. The dose is too low to achieve the weight loss seen in the STEP trials. Clinically, many patients do lose weight on 1 mg, but average results are 5 to 7 percentage points lower than at 2.4 mg.

Conversely, using 2.4 mg for diabetes is overkill. The incremental A1C benefit is small, and the side effect burden (nausea, vomiting, diarrhea) is higher at 2.4 mg.

Insurance coverage often drives dose selection rather than clinical appropriateness. A patient with obesity and type 2 diabetes might get Ozempic 1 mg covered (for diabetes) but not Wegovy 2.4 mg (for obesity), even though the latter would address both conditions more effectively.

When semaglutide is NOT appropriate

Semaglutide has absolute and relative contraindications:

Absolute contraindications (do not prescribe):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• History of severe allergic reaction to semaglutide or any excipient
• Pregnancy (category C, animal studies show fetal harm)

Relative contraindications (use with caution or avoid):

• History of pancreatitis (GLP-1 agonists carry a small but real pancreatitis risk)
• Severe gastroparesis (semaglutide slows gastric emptying further)
• Active gallbladder disease (rapid weight loss increases gallstone risk)
• Diabetic retinopathy (SUSTAIN-6 showed a small increase in retinopathy complications, likely due to rapid glucose lowering)
• Renal impairment (no dose adjustment needed, but dehydration from GI side effects can worsen kidney function)
• History of suicidal ideation (ongoing monitoring for neuropsychiatric effects, though causality is unclear)

Semaglutide is also inappropriate when the patient's goal is short-term cosmetic weight loss (e.g., losing 10 pounds for a wedding). The medication is FDA-approved for chronic weight management, meaning indefinite use. Stopping after short-term use leads to weight regain in most patients (STEP-4 trial showed 7% weight regain within 48 weeks of stopping).

The decision tree for appropriateness:

If the patient has type 2 diabetes and A1C >7% despite metformin:

• Semaglutide is appropriate. Start at diabetes dosing (0.5 to 1 mg weekly).

If the patient has BMI ≥30, or BMI ≥27 with hypertension, dyslipidemia, or obstructive sleep apnea:

• Semaglutide is appropriate. Start at weight-loss dosing (titrate to 2.4 mg weekly).

If the patient has type 2 diabetes and established cardiovascular disease:

• Semaglutide is appropriate for cardiovascular risk reduction. Use diabetes dosing (0.5 to 1 mg weekly).

If the patient has BMI 25 to 26.9 with no comorbidities:

• Semaglutide is off-label. Insurance will not cover. Clinical benefit is uncertain.

If the patient has a personal history of MTC or MEN 2:

• Do not prescribe. Refer to endocrinology for alternative options.

FormBlends clinical pattern: what we see in 1,800+ semaglutide starts

Across our platform's prescribing data, three patterns emerge consistently:

Pattern 1: Indication drift during titration. About 40% of patients starting semaglutide for diabetes (Ozempic dosing) ask to escalate to weight-loss dosing (2.4 mg) after seeing initial weight loss at 0.5 to 1 mg. The conversation usually happens around week 12. Clinically, this makes sense. If the patient has both diabetes and obesity, treating both conditions with a single medication at the appropriate dose is more effective than undertreating the obesity.

Pattern 2: The 1.7 mg stall. In the Wegovy titration protocol, 1.7 mg is the second-to-last step before 2.4 mg maintenance. We see a disproportionate number of patients who stay at 1.7 mg indefinitely rather than completing the escalation. The reasons vary: side effects at 1.7 mg that make patients hesitant to go higher, insurance denying the 2.4 mg dose, or "good enough" weight loss at 1.7 mg. The STEP trials did not test 1.7 mg as a maintenance dose, so long-term efficacy data at that dose does not exist.

Pattern 3: Rebound weight regain drives restarts. Patients who stop semaglutide after 6 to 12 months (often due to cost or perceived goal achievement) regain an average of 60 to 70% of lost weight within 12 months. Many return requesting to restart. The STEP-4 trial (Rubino et al., JAMA, 2021) formalized this: patients randomized to switch from semaglutide to placebo regained two-thirds of their lost weight within 48 weeks. The implication is that semaglutide works as long as you take it, similar to blood pressure medication.

These patterns reinforce that semaglutide is a chronic disease medication, not a short-term intervention. The patients who succeed long-term treat it as a maintenance therapy, not a temporary fix.

FAQ

What conditions is semaglutide FDA-approved to treat? Semaglutide is FDA-approved for type 2 diabetes (to improve blood sugar control), chronic weight management in adults with obesity or overweight with weight-related health conditions, and reducing cardiovascular events in adults with type 2 diabetes and heart disease.

Can semaglutide be used for weight loss if I don't have diabetes? Yes. Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity like hypertension or dyslipidemia. You do not need diabetes to qualify.

Is semaglutide only for diabetes? No. Semaglutide has three separate FDA approvals: diabetes, weight loss, and cardiovascular risk reduction. The weight-loss indication does not require diabetes. Many patients use semaglutide exclusively for obesity without any blood sugar issues.

What is the difference between Ozempic and Wegovy? Both are semaglutide injections. Ozempic is approved for type 2 diabetes at doses up to 1 mg weekly. Wegovy is approved for weight loss at 2.4 mg weekly. The active ingredient and mechanism are identical. The difference is the approved dose and indication.

Can semaglutide prevent diabetes? Semaglutide is not FDA-approved for pre-diabetes or diabetes prevention. Some clinicians prescribe it off-label for patients with pre-diabetes who have not responded to lifestyle changes. The mechanism (improved insulin sensitivity, weight loss) suggests it would work, but no large trial has tested this as a primary outcome.

Does semaglutide reduce heart attack risk? Yes, in specific populations. The SUSTAIN-6 trial showed a 26% reduction in major cardiovascular events in adults with type 2 diabetes and established heart disease. The SELECT trial showed a 20% reduction in adults with obesity and heart disease but without diabetes. The benefit appears to extend beyond glucose control.

Can I use semaglutide for PCOS? Semaglutide is not FDA-approved for PCOS. Small studies show it improves insulin resistance, reduces androgen levels, and restores menstrual cycles in women with PCOS. Many endocrinologists prescribe it off-label for PCOS patients with obesity or insulin resistance.

Is semaglutide safe if I have fatty liver disease? Semaglutide is not FDA-approved for fatty liver disease, but weight loss improves liver fat and inflammation in NAFLD. Some hepatologists prescribe GLP-1 agonists off-label for NASH. Ongoing trials are testing semaglutide specifically for liver disease, but results are not yet published.

How does semaglutide work for weight loss? Semaglutide mimics GLP-1, a hormone that reduces appetite, increases feelings of fullness, and slows stomach emptying. At 2.4 mg weekly, these effects are strong enough to produce an average 15% weight loss over 68 weeks when combined with diet and exercise.

Can semaglutide cure diabetes? No. Semaglutide improves blood sugar control while you take it, but it does not cure diabetes. If you stop the medication, blood sugar typically returns toward baseline within weeks to months. Some patients achieve remission (A1C <6.5% off medication) through weight loss, but this requires sustained lifestyle changes.

What is compounded semaglutide used for? Compounded semaglutide is used for the same indications as brand-name versions: type 2 diabetes and chronic weight management. It is prepared by compounding pharmacies and is not FDA-approved, but it contains the same active ingredient and follows the same dosing protocols.

Can semaglutide be used for cosmetic weight loss? Semaglutide is FDA-approved for chronic weight management in patients with obesity or overweight with comorbidities, not for cosmetic weight loss in people at healthy weight. Using it for short-term cosmetic goals is off-label and not supported by clinical trial evidence. Weight regain after stopping is common.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
2. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
3. Aroda VR et al. Efficacy and safety of oral semaglutide versus placebo added to background glucose-lowering therapy in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial (PIONEER 3). Lancet. 2019.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
6. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021.
7. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
8. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
9. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
10. Elkind-Hirsch K et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 2022.
11. Newsome PN et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. New England Journal of Medicine. 2021.
12. Klausen MK et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. Journal of Clinical Psychiatry. 2024.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
14. Davies M et al. Gastric emptying and glucose metabolism in patients treated with semaglutide. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.